면역 레퍼토리 시퀀싱 시장 규모, 점유율, 동향 분석 보고서 : 제품 및 서비스별, 유형별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)
Immune Repertoire Sequencing Market Size, Share & Trends Analysis Report By Product & Service, By Type, By Application, By End-use, By Region, And Segment Forecasts, 2025 - 2033
상품코드
:
1888665
리서치사
:
Grand View Research
발행일
:
2025년 11월
페이지 정보
:
영문 120 Pages
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
샘플 요청 목록에 추가
면역 레퍼토리 시퀀싱 시장 요약
세계의 면역 레퍼토리 시퀀싱 시장 규모는 2024년에 3억 2,820만 달러로 추정되며, 2033년까지 8억 9,420만 달러에 달할 것으로 예측됩니다.
2025년부터 2033년까지 CAGR 11.89%로 성장할 것으로 예상됩니다. 차세대 시퀀싱 기술 도입 확대, 면역치료 및 백신 개발 적용, 정밀의료 연구 투자가 시장 성장을 견인하고 있습니다.
목차 제1장 조사 방법과 범위
제2장 주요 요약
제3장 면역 레퍼토리 시퀀싱 시장 변수, 동향 및 범위
시장 계통 전망
시장 역학
면역 레퍼토리 시퀀싱 시장 분석 툴
업계 분석 - Porter's
PESTEL 분석
제4장 면역 레퍼토리 시퀀싱 시장 : 제품 및 서비스별 추정·동향 분석
세계의 면역 레퍼토리 시퀀싱 시장 : 제품 및 서비스별 변동 분석
세계의 면역 레퍼토리 시퀀싱 시장 규모와 동향 분석 : 제품 및 서비스별, 2021-2033년
기기
어세이 키트 및 시약
서비스
제5장 면역 레퍼토리 시퀀싱 시장 : 유형별 추정·동향 분석
세계의 면역 레퍼토리 시퀀싱 시장 : 유형별 변동 분석
세계의 면역 레퍼토리 시퀀싱 시장 규모와 동향 분석 : 유형별, 2021-2033년
벌크 면역 레퍼토리 시퀀싱
단일세포 면역 레퍼토리 시퀀싱
제6장 면역 레퍼토리 시퀀싱 시장 : 용도별 추정·동향 분석
세계의 면역 레퍼토리 시퀀싱 시장 : 용도별 변동 분석
세계의 면역 레퍼토리 시퀀싱 시장 규모와 동향 분석 : 용도별, 2021-2033년
종양학 및 암 면역치료
자가면역질환·염증성 질환
감염증·백신 개발
이식·면역 관용
기타
제7장 면역 레퍼토리 시퀀싱 시장 : 최종 용도별 추정·동향 분석
세계의 면역 레퍼토리 시퀀싱 시장 : 최종 용도별 변동 분석
세계의 면역 레퍼토리 시퀀싱 시장 규모와 동향 분석 : 최종 용도별, 2021-2033년
학술·조사기관
제약·바이오테크놀러지 기업
기타
제8장 면역 레퍼토리 시퀀싱 시장 : 지역별 추정·동향 분석
지역별 시장 점유율 분석, 2024년 및 2033년
지역별 시장 대시보드
시장 규모 및 예측 동향 분석, 2021-2033년
북미
유럽
영국
독일
프랑스
이탈리아
스페인
노르웨이
스웨덴
덴마크
아시아태평양
라틴아메리카
중동 및 아프리카
남아프리카공화국
사우디아라비아
아랍에미리트
쿠웨이트
제9장 경쟁 구도
기업/경쟁 분류
전략 매핑
2024년의 기업 시장 상황 분석
기업 개요/리스트
QIAGEN
New England Biolabs
Takara Bio
Illumina, Inc.
iRepertoire
BGI
Danaher
Creative Biolabs
Nucleus Biotech
Celemics, Inc.
KSM
영문 목차
Immune Repertoire Sequencing Market Summary
The global immune repertoire sequencing market size was estimated at USD 328.2 million in 2024 and is projected to reach USD 894.2 million by 2033, growing at a CAGR of 11.89% from 2025 to 2033. The increasing adoption of next-generation sequencing technologies, applications in immunotherapy and vaccine development, and investments in precision medicine research drive the market growth.
Global Immune Repertoire Sequencing Market Report Segmentation
This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global immune repertoire sequencing market report based on product & service, type, application, end-use, and region:
Product & Service Outlook (Revenue, USD Million, 2021 - 2033)
Instruments
Assay Kits & Reagents
Services
Type Outlook (Revenue, USD Million, 2021 - 2033)
Bulk immune repertoire sequencing
Single cell immune repertoire sequencing
Application Outlook (Revenue, USD Million, 2021 - 2033)
Oncology & Cancer Immunotherapy
Autoimmune & Inflammatory Diseases
Infectious Diseases & Vaccine Development
Transplantation & Immune Tolerance
Others
End-use Outlook (Revenue, USD Million, 2021 - 2033)
Academic & Research Institutes
Pharmaceutical & Biotechnology Companies
Others
Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
Europe
Germany
UK
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
China
Japan
India
South Korea
Australia
Thailand
Latin America
MEA
South Africa
Saudi Arabia
UAE
Kuwait
Table of Contents Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.2.1. Product & Service Segment
1.2.2. Type Segment
1.2.3. Application Segment
1.2.4. End use Segment
1.3. Information analysis
1.4. Market formulation & data visualization
1.5. Data validation & publishing
1.6. Information Procurement
1.7. Information or Data Analysis
1.8. Market Formulation & Validation
1.9. Market Model
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Insights Landscape
Chapter 3. Immune Repertoire Sequencing Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Growing adoption of personalized medicine
3.2.1.2. Rising prevalence of immune-related diseases
3.2.1.3. Advancements in high-throughput sequencing technologies
3.2.2. Market restraint analysis
3.2.2.1. High cost of sequencing technologies
3.2.2.2. Complex data analysis and interpretation
3.3. Immune Repertoire Sequencing Market Analysis Tools
3.3.1. Industry Analysis - Porter's
3.3.2. PESTEL Analysis
Chapter 4. Immune Repertoire Sequencing Market: Product & Service Estimates & Trend Analysis
4.1. Product & Service Segment Dashboard
4.2. Global Immune Repertoire Sequencing Market Product & Service Movement Analysis
4.3. Global Immune Repertoire Sequencing Market Size & Trend Analysis, by Product & Service, 2021 to 2033 (USD Million)
4.4. Instruments
4.4.1. Instruments market estimates and forecasts 2021 to 2033 (USD Million)
4.5. Assay Kits & Reagents
4.5.1. Assay Kits & Reagents market estimates and forecasts 2021 to 2033 (USD Million)
4.5.2. TCR kits
4.5.2.1. TCR kits market estimates and forecasts 2021 to 2033 (USD Million)
4.5.3. BCR kits
4.5.3.1. BCR kits market estimates and forecasts 2021 to 2033 (USD Million)
4.5.4. Others
4.5.4.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
4.6. Services
4.6.1. Services market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 5. Immune Repertoire Sequencing Market: Type Estimates & Trend Analysis
5.1. Type Segment Dashboard
5.2. Global Immune Repertoire Sequencing Market Type Movement Analysis
5.3. Global Immune Repertoire Sequencing Market Size & Trend Analysis, by Type, 2021 to 2033 (USD Million)
5.4. Bulk immune-repertoire sequencing
5.4.1. Bulk immune-repertoire sequencing market estimates and forecasts 2021 to 2033 (USD Million)
5.5. Single-cell immune-repertoire sequencing
5.5.1. Single-cell immune-repertoire sequencing market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 6. Immune Repertoire Sequencing Market: Application Estimates & Trend Analysis
6.1. Application Segment Dashboard
6.2. Global Immune Repertoire Sequencing Market Application Movement Analysis
6.3. Global Immune Repertoire Sequencing Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
6.4. Oncology & Cancer Immunotherapy
6.4.1. Oncology & Cancer Immunotherapy market estimates and forecasts 2021 to 2033 (USD Million)
6.5. Autoimmune & Inflammatory Diseases
6.5.1. Autoimmune & Inflammatory Diseases market estimates and forecasts 2021 to 2033 (USD Million)
6.6. Infectious Diseases & Vaccine Development
6.6.1. Infectious Diseases & Vaccine Development market estimates and forecasts 2021 to 2033 (USD Million)
6.7. Transplantation & Immune Tolerance
6.7.1. Transplantation & Immune Tolerance market estimates and forecasts 2021 to 2033 (USD Million)
6.8. Others
6.8.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 7. Immune Repertoire Sequencing Market: End Use Estimates & Trend Analysis
7.1. End Use Segment Dashboard
7.2. Global Immune Repertoire Sequencing Market End Use Movement Analysis
7.3. Global Immune Repertoire Sequencing Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
7.4. Academic & Research Institutes
7.4.1. Academic & Research Institutes market estimates and forecasts 2021 to 2033 (USD Million)
7.5. Pharmaceutical & Biotechnology Companies
7.5.1. Pharmaceutical & Biotechnology Companies market estimates and forecasts 2021 to 2033 (USD Million)
7.6. Others
7.6.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 8. Immune Repertoire Sequencing Market: Regional Estimates & Trend Analysis by Product & Service, Type, Application, and End Use
8.1. Regional Market Share Analysis, 2024 & 2033
8.2. Regional Market Dashboard
8.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
8.4. North America
8.4.1. North America market estimates and forecasts 2021 to 2033 (USD Million)
8.4.2. U.S.
8.4.2.1. Key country dynamics
8.4.2.2. Regulatory framework
8.4.2.3. Competitive scenario
8.4.2.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
8.4.3. Canada
8.4.3.1. Key country dynamics
8.4.3.2. Regulatory framework
8.4.3.3. Competitive scenario
8.4.3.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
8.4.4. Mexico
8.4.4.1. Key country dynamics
8.4.4.2. Regulatory framework
8.4.4.3. Competitive scenario
8.4.4.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
8.5. Europe
8.5.1. Europe market estimates and forecasts 2021 to 2033 (USD Million)
8.5.2. UK
8.5.2.1. Key country dynamics
8.5.2.2. Regulatory framework
8.5.2.3. Competitive scenario
8.5.2.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
8.5.3. Germany
8.5.3.1. Key country dynamics
8.5.3.2. Regulatory framework
8.5.3.3. Competitive scenario
8.5.3.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
8.5.4. France
8.5.4.1. Key country dynamics
8.5.4.2. Regulatory framework
8.5.4.3. Competitive scenario
8.5.4.4. France market estimates and forecasts 2021 to 2033 (USD Million)
8.5.5. Italy
8.5.5.1. Key country dynamics
8.5.5.2. Regulatory framework
8.5.5.3. Competitive scenario
8.5.5.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
8.5.6. Spain
8.5.6.1. Key country dynamics
8.5.6.2. Regulatory framework
8.5.6.3. Competitive scenario
8.5.6.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
8.5.7. Norway
8.5.7.1. Key country dynamics
8.5.7.2. Regulatory framework
8.5.7.3. Competitive scenario
8.5.7.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
8.5.8. Sweden
8.5.8.1. Key country dynamics
8.5.8.2. Regulatory framework
8.5.8.3. Competitive scenario
8.5.8.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
8.5.9. Denmark
8.5.9.1. Key country dynamics
8.5.9.2. Regulatory framework
8.5.9.3. Competitive scenario
8.5.9.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
8.6. Asia Pacific
8.6.1. Asia Pacific market estimates and forecasts 2021 to 2033 (USD Million)
8.6.2. Japan
8.6.2.1. Key country dynamics
8.6.2.2. Regulatory framework
8.6.2.3. Competitive scenario
8.6.2.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
8.6.3. China
8.6.3.1. Key country dynamics
8.6.3.2. Regulatory framework
8.6.3.3. Competitive scenario
8.6.3.4. China market estimates and forecasts 2021 to 2033 (USD Million)
8.6.4. India
8.6.4.1. Key country dynamics
8.6.4.2. Regulatory framework
8.6.4.3. Competitive scenario
8.6.4.4. India market estimates and forecasts 2021 to 2033 (USD Million)
8.6.5. Australia
8.6.5.1. Key country dynamics
8.6.5.2. Regulatory framework
8.6.5.3. Competitive scenario
8.6.5.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
8.6.6. South Korea
8.6.6.1. Key country dynamics
8.6.6.2. Regulatory framework
8.6.6.3. Competitive scenario
8.6.6.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
8.6.7. Thailand
8.6.7.1. Key country dynamics
8.6.7.2. Regulatory framework
8.6.7.3. Competitive scenario
8.6.7.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
8.7. Latin America
8.7.1. Latin America market estimates and forecasts 2021 to 2033 (USD Million)
8.7.2. Brazil
8.7.2.1. Key country dynamics
8.7.2.2. Regulatory framework
8.7.2.3. Competitive scenario
8.7.2.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
8.7.3. Argentina
8.7.3.1. Key country dynamics
8.7.3.2. Regulatory framework
8.7.3.3. Competitive scenario
8.7.3.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
8.8. MEA
8.8.1. MEA market estimates and forecasts 2021 to 2033 (USD Million)
8.8.2. South Africa
8.8.2.1. Key country dynamics
8.8.2.2. Regulatory framework
8.8.2.3. Competitive scenario
8.8.2.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
8.8.3. Saudi Arabia
8.8.3.1. Key country dynamics
8.8.3.2. Regulatory framework
8.8.3.3. Competitive scenario
8.8.3.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
8.8.4. UAE
8.8.4.1. Key country dynamics
8.8.4.2. Regulatory framework
8.8.4.3. Competitive scenario
8.8.4.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
8.8.5. Kuwait
8.8.5.1. Key country dynamics
8.8.5.2. Regulatory framework
8.8.5.3. Competitive scenario
8.8.5.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 9. Competitive Landscape
9.1. Company/Competition Categorization
9.2. Strategy Mapping
9.3. Company Market Position Analysis, 2024
9.4. Company Profiles/Listing
9.4.1. QIAGEN
9.4.1.1. Company overview
9.4.1.2. Financial performance
9.4.1.3. Product benchmarking
9.4.1.4. Strategic initiatives
9.4.2. New England Biolabs
9.4.2.1. Company overview
9.4.2.2. Financial performance
9.4.2.3. Product benchmarking
9.4.2.4. Strategic initiatives
9.4.3. Takara Bio
9.4.3.1. Company overview
9.4.3.2. Financial performance
9.4.3.3. Product benchmarking
9.4.3.4. Strategic initiatives
9.4.4. Illumina, Inc.
9.4.4.1. Company overview
9.4.4.2. Financial performance
9.4.4.3. Product benchmarking
9.4.4.4. Strategic initiatives
9.4.5. iRepertoire
9.4.5.1. Company overview
9.4.5.2. Financial performance
9.4.5.3. Product benchmarking
9.4.5.4. Strategic initiatives
9.4.6. BGI
9.4.6.1. Company overview
9.4.6.2. Financial performance
9.4.6.3. Product benchmarking
9.4.6.4. Strategic initiatives
9.4.7. Danaher
9.4.7.1. Company overview
9.4.7.2. Financial performance
9.4.7.3. Product benchmarking
9.4.7.4. Strategic initiatives
9.4.8. Creative Biolabs
9.4.8.1. Company overview
9.4.8.2. Financial performance
9.4.8.3. Product benchmarking
9.4.8.4. Strategic initiatives
9.4.9. Nucleus Biotech
9.4.9.1. Company overview
9.4.9.2. Financial performance
9.4.9.3. Product benchmarking
9.4.9.4. Strategic initiatives
9.4.10. Celemics, Inc.
9.4.10.1. Company overview
9.4.10.2. Financial performance
9.4.10.3. Product benchmarking
9.4.10.4. Strategic initiatives
관련자료
